Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance
Paris (France), 25 October 2018 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2018.
Financial highlights
- Q3 2018 Group sales growth of 20.2%1 driven by Specialty Care sales growth of 24.2%1 reflecting strong momentum for Somatuline® and Dysport®, continued sequential sales growth for Cabometyx® and Onivyde®, and growth of Consumer Healthcare sales of 5.0%2
- YTD Group sales growth of 21.1%1 fueled by strong Specialty Care sales growth of 25.8%1 and Consumer Healthcare sales growth of 2.9%2
- Full Year 2018 guidance confirmed with Group sales growth of greater than 19.0%1 and core operating margin of around 29.0% of sales
Pipeline highlights
- Positive CHMP (Committee for Medicinal Products for Human Use) opinion for Cabometyx® for the treatment of second-line patients with hepatocellular carcinoma (HCC)
- First European approval for the new Somatuline® delivery system
Attachment
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Ipsen announces changes to its Executive Committee
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication